Bellerophon Therapeutics stock opened at $0.01 on Friday. The firm has a market cap of $146,796.00, a price-to-earnings ratio of -0.01 and a beta of 0.74. Bellerophon Therapeutics has a 52 week ...

Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report) and keeping the price target at $8.00. Discover outperforming stocks and invest ...

Freeways are by far the safest roads in Germany, "lighting has no influence on the number of accidents," said Kerstin Finis-Keck, Deputy Director of the North-East branch of Autobahn GmbH. An unlit ...

Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the initiation of a Phase 2 ...

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced ...

About Autobahn Therapeutics Autobahn Therapeutics is a biotechnology company developing a portfolio of neuropsychiatric and neuroimmunologic clinical candidates leveraging its brain-targeting ...